The recently discovered MLT/MALT1 gene is fused with the API2 gene in the t(11;18)(q21;q21), which characterizes about one-third of MALT lymphomas. In order to screen for variant translocations and amplifications of MLT/MALT1, we have developed a novel, undirected two-color interphase fluorescence in situ hybridization (FISH) assay with two PAC clones flanking MLT/MALT1. This assay was applied to 108 marginal zone B-cell lymphomas (MZBCLs), including 72 extranodal MALT lymphomas, 17 nodal, and 19 splenic MZBCL. In 19 MALT lymphomas (26%), but in none of the nodal or splenic MZBCL, separated hybridization signals of the MLT/MALT1 flanking probes, were found. Further FISH analyses showed that 12 of these 19 cases displayed the classical t(11;18) and the remaining seven cases revealed the novel t(14;18)(q32;q21), involving the MLT/MALT1 and IGH genes. The frequency at which these translocations occurred varied significantly with the primary location of disease. The t(11;18) was mainly detected in gastrointestinal MALT lymphomas, whereas the t(14;18) occurred in MALT lymphomas of the parotid gland and the conjunctiva. Amplification of MLT/MALT1 was not observed in any of the lymphomas analyzed. We conclude that the translocations t(11;18)(q21;q21) and t(14;18)(q21;q32) represent the main structural aberrations involving MLT/MALT1 in MALT lymphomas, whereas true amplifications of MLT/MALT1 occur rarely in MZBCL.
Introduction
The MLT/MALT1 gene was discovered due to its involvement in the translocation t(11;18)(q21;q21) associated with extranodal marginal zone B-cell lymphoma (MZBCL) of the MALT type and characterizes about one-third of the cases. [1] [2] [3] [4] [5] [6] The t(11;18)(q21;q21) leads to a fusion of the apoptosis inhibitor gene API2 on chromosome 11 and the novel MLT/MALT1 gene, a human paracaspase, on chromosome 18. 3, 7, 8 The pathogenetic relevant event involves the derivative chromosome 11 and leads to linkage of the three baculovirus IAP repeat (BIR) domains present in the N-terminus of API2 and a variable part of MLT/MALT1, which always contains the caspase p20-like domain. 3, 7, [9] [10] [11] The chimeric protein effectively activates NF-kB, a potential prosurvival signal in B cells. 12, 13 The t(11;18)(q21;q21) has mainly been observed in lowgrade MALT lymphomas of the gastrointestinal tract and the lung. 2, [4] [5] [6] 14 Recent studies have also shown that the t(11;18) confers important prognostic implications, since this translocation has been associated with gastric MALT lymphomas that do not respond to Helicobacter pylori eradication therapy and H. pylori-negative gastric MALT lymphomas with a rather aggressive clinical course. 15, 16 Recently, the t(14;18)(q32;q21) involving the MLT/MALT1 and IGH genes has been identified as a new frequent chromosomal translocation in MALT lymphomas. 17, 18 The t(14;18) characterizes MALT lymphomas in locations, such as liver, skin, parotid gland, and ocular adnexa that rarely harbor the t(11;18)(q21;q21). 18 In addition to gene rearrangements by translocations, gene amplification represents another mechanism in the pathogenesis and disease progression of non-Hodgkin's lymphomas (NHL). Such amplifications frequently involve the BCL2 gene on 18q21. 17 However, the incidence of MLT/MALT1 amplifications in NHL, especially MALT lymphomas, is unknown.
To screen for all kind of translocations and amplifications involving the MLT/MALT1 gene, we have developed a novel, undirected two-color fluorescence in situ hybridization (FISH) assay with two PAC clones flanking the MLT/MALT1 gene. This assay was applied to a large series of MZBCL, including 72 extranodal, 17 nodal, and 19 splenic cases.
Materials and methods

Patients' samples
In all, 108 cases of MZBCL were collected based on the availability of fixed cells, frozen, or paraffin-embedded tissue from the University Hospital Hamburg-Eppendorf, Hamburg, Germany (n ¼ 60), the Centre Hospitalier Universitaire Henri Mondor, Créteil, France (n ¼ 26), and the Center for Human Genetics of University of Leuven, Leuven, Belgium (n ¼ 22). The 108 MZBCL included 72 extranodal MALT lymphomas from various locations (stomach (n ¼ 31), parotid gland (n ¼ 28),
, and submaxillary gland (n ¼ 1)), 17 nodal, and 19 splenic MZBCL. All MALT lymphomas were studied at the time of primary diagnosis. All lymphomas were classified according to the WHO classification and showed the typical histological features of MZBCL.
Preparation of the specimens
For the present study, we used freshly prepared cytospin preparations of cells isolated by manual disaggregation from frozen tumor tissues (n ¼ 58) and formalin-fixed paraffinembedded tissues (n ¼ 24), or cells that were fixed with methanol-acetic acid and had been previously cultured (n ¼ 26). The preparation of methanol-acetic acid fixed and frozen cells was performed as previously described. 5 The paraffin-embedded cells were collected by carefully scraping off paraffin blocks. The scraped material was deparaffinized with two 10 min incubations in xylene substitute Rotihistol (Roth, Karlsruhe, Germany) and rehydrated in a graded ethanol series (100, 90, and 70%, 2 min each). The samples were then enzymatically digested with a freshly prepared solution containing 10 ml of proteinase K (10 mg/ml) (Sigma, Steinheim, Germany) for 30 min at 451C and washed in 1 Â phosphatebuffered saline (PBS). Thereafter, the cells were incubated for 30 min in 0.075 mol/l KCl, washed twice in 1 Â PBS, and used for preparation of cytospins. The cytospins were fixed for 10 min in methanol-acetic acid followed by 5 min incubation in a solution containing 1% formaldehyde, 1 Â PBS, and 50 mmol/l magnesium dichloride (MgCl 2 ). After a short wash in 1 Â PBS and dehydration in a graded ethanol series, the preparations were subjected to FISH analysis.
Probe selection
Dual-color interphase FISH was performed using two differen- Cases with separated MLT/MALT1 signals were further investigated using specific probe sets detecting the t(11;18)(q21;q21) and the t(14;18)(q32;q21). The t(11;18)(q21;q21) was analyzed with PAC clones 59N7 (MLT/ MALT1 gene) in combination with 166G16 (API2 gene). 5 The novel t(14;18)(q32;q21) was shown with PACs 59N7 and cosmid C a1 (hybridizing to the alpha constant region of the IGH locus). 19 Amplification of MLT/MALT1 was defined as described and validated for the detection of oncogene amplification. 20, 21 The criteria included the presence of individual tumor cells with tight clusters of MLT/MALT1 interphase FISH signals, with more than five MLT/MALT1 signals per cell or with two-fold higher number of MLT/MALT1 than D18Z1 (centromere 18) signals. All cases with more or less than two MLT/MALT1-specific signals were further analyzed with DNA probes hybridizing to the BCL2 gene on 18q21 (YAC yA153A6) 22 and the centromeric regions of chromosomes 18 (D18Z1) and 11 (D11Z1) (both from Oncor, Gaithersburg, MD, USA).
Fluorescence in situ hybridization
DNA labeling with biotin-(PAC 117B5) and digoxigenin-dUTP (PAC 59N7) by nick translation and FISH were performed according to standard methods as previously described. 5, 23 For the cytospin preparations from frozen tumor tissue, 80 ng of PAC 59N7, 50 ng of PAC 117B5, and 11 mg of Cot-1 DNA, for the fixed cell preparations, 140 ng of PAC 59N7, 140 ng of PAC 117B5, and 11 mg of Cot-1 DNA, and for the preparations obtained from the paraffin-embedded tumor tissue, 160 ng PAC 117B5, 160 ng PAC 59N7, and 14 mg Cot-1 DNA were used. The probe DNA was dissolved in 5 ml of hybridization mixture, applied to the slide, and covered with a round 13 mm coverslip. A total of 200 well-preserved, separately located interphase cells with clearly visible, distinct signals were analyzed in each case.
Determination of cutoff levels
The cutoff levels for the different probe sets were determined by analyzing five normal control samples from fixed cells and cytospin preparations from frozen and paraffin-embedded tissue. The cutoff levels were defined by the mean plus three standard deviations of the respective result in the experiments with the normal controls. The cutoff levels were determined as follows: MLT/MALT1-assay (PAC 59N7 and PAC 117B5) on fixed cells 4.9%, on frozen material 6.3%, on paraffinembedded material 5%; t(14;18) assay (PAC 59N7 and cosmid C a1 ) on fixed cells 4.6%, on frozen material 6.5%, on paraffinembedded material 6.6%; and t(11;18) assay (PAC 59N7 and PAC 166G16) on fixed cells 4.1%, on frozen material 4.4%, on paraffin-embedded material 4.4%.
Results
We analyzed 108 MZBCL including 72 extranodal, 17 nodal, and 19 splenic cases with a novel two-color interphase FISH assay using two PAC clones 59N7 and PAC 117B5 flanking the MLT/MALT1 gene (Figure 1a) . Separated MLT/MALT1-specific signals, indicating a structural chromosomal abnormality involving MLT/MALT1, were observed in 19 cases, all of which represented extranodal MALT lymphomas (Figure 1b) . Therefore, the prevalence of translocations involving MLT/MALT1 was 26% (19 of 72 cases) in the group of extranodal MALT lymphomas, whereas none of the nodal and splenic MZBCL revealed any MLT/MALT1-associated translocation ( Table 1) .
The MALT lymphomas with separated MLT/MALT1-specific signals were confined to the following organs: stomach (n ¼ 7), intestine (n ¼ 3), parotid gland (n ¼ 6), lung (n ¼ 1), submaxillary gland (n ¼ 1), and conjunctiva (n ¼ 1). The latter cases were further analyzed by interphase FISH for the presence of the t(11;18)(q21;q21) and the t(14;18)(q32;q21). The t(11;18) was found in 12 cases (17% of the MALT lymphomas) and the t(14;18) was detected in seven cases (10% of the MALT lymphomas) ( Table 1) . The frequency at which these translocations occurred varied significantly with the primary location of disease. The t(11;18)-positive cases comprised mainly MALT lymphomas of the gastrointestinal tract (28% of these cases), one MALT lymphoma of the lung (only one case analyzed), and one MALT lymphoma of the submaxillary gland (only one case analyzed). The t(14;18) occurred exclusively in MALT lymphomas located in the parotid gland and the conjunctiva (23% of these cases) ( Table 1 ). An autoimmune myoepithelial sialadenitis (MESA) associated with Sjö gren's syndrome was diagnosed in all of the six patients with a MALT lymphoma of the parotid gland.
Amplification of MLT/MALT1 was not found in any of the 108 MZBCL. However, trisomy or polysomy of chromosome 18 revealed by three to five MLT/MALT1-, BCL2-, and centromere 18-specific hybridization signals was observed in 13 cases, including four MALT lymphomas (two cases with trisomy 18, one case with tetrasomy 18, one case with pentasomy 18), two nodal MZBCL (two cases with trisomy 18), and seven splenic MZBCL (seven cases with trisomy 18) ( Table 2 ). The splenic MZBCL showed the highest frequency of trisomy 18 with seven out of 19 cases (37%) revealing this abnormality. In all 13 cases with aneuploidy of chromosome 18, only two centromere 11-specific hybridization signals were detected (Table 2) .
Deletions involving MLT/MALT1 and BCL2, but not the centromeric region of chromosome 18, were found in two MALT lymphomas (Table 2) .
Discussion
This is the first study that screened a series of MZBCL for all kinds of translocations and amplifications/over-representations involving the recently discovered MLT/MALT1 gene on chromosome 18q21. To do so, we have developed an undirected dualcolor interphase FISH assay with two PAC clones flanking the MLT/MALT1 gene. A separation of the hybridization signals of the two PAC clones indicates a disruption of the MLT/MALT1 gene, for example by a translocation. This assay can easily be applied to fresh and archival tumor tissue, as paraffin-embedded tissue, and therefore enables the retrospective and prospective analysis of large series. 3  3  3  2  4  MALT breast  3  3  3  2  5  Nodal MZBCL  3  3  3  2  6  Nodal MZBCL  3  3  3  2  7  Splenic MZBCL  3  3  3  2  8  Splenic MZBCL  3  3  3  2  9  Splenic MZBCL  3  3  3  2  10  Splenic MZBCL  3  3  3  2  11  Splenic MZBCL  3  3  3  2  12  Splenic MZBCL  3  3  3  2  13  Splenic MZBCL  3  3  3  2  14  MALT stomach  1  1  2  2  15 MALT stomach 1 1 2 2
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Using this assay we have analyzed 108 MZBCL, including 72 extranodal MALT lymphomas from various localizations, 17 nodal, and 19 splenic MZBCL. Separated hybridization signals of the MLT/MALT1 flanking probes were found in 19 cases, all of which represented extranodal MALT lymphomas. None of the nodal or splenic lymphomas showed a translocation involving MLT/MALT1. These findings suggest that chromosomal translocations involving MLT/MALT are exclusively associated with extranodal MZBCL of the MALT type. Similar results have been published for the t(11;18), which specifically characterizes extranodal MALT lymphomas and has not been observed in any other subtype of NHL. 2, 4, 5, 11 In order to determine the unknown translocation partner of MLT/MALT1, all 19 cases showing separated MLT/MALT1-specific hybridization signals were further analyzed by FISH with probes sets detecting the t(11;18)(q21;q21) and t(14;18)(q32;q21), respectively. In all 19 cases, either the t(11;18) or the t(14;18) were detected. No other structural chromosomal abnormalities involving MLT/MALT1 were found. The t(11;18) was observed in 10 gastrointestinal, one pulmonary, and one MALT lymphoma of the submaxillary glands. The novel t(14;18) rearranging the MLT/MALT1 and IGH genes was found in seven MALT lymphomas of the parotid gland and one MALT lymphoma of the ocular conjunctiva. These data demonstrate for the first time that the t(11;18)(q21;q21) and t(14;18)(q32;q21) represent the two main translocations involving MLT/MALT1 in MALT lymphomas and that other MLT/ MALT1-associated rearrangements are at least rare.
In the present study, the t(11;18) was found in 17% of all analyzed MALT lymphomas, including 28% of MALT lymphomas of the gastrointestinal tract, one MALT lymphoma of the lung, and one MALT lymphoma of the submaxillary gland. Interestingly, in none of the MALT lymphomas infiltrating these organs the t(14;18) was detected. The incidence of the t(11;18) in our study is comparable with previous data reported in the literature. 5, 10, 11, 14, 24 Ye and co-workers screened 417 cases of MALT lymphomas from eight major sites by RT-PCR for the presence of the t(11;18) and found this translocation at highest frequencies in MALT lymphomas from the lung (38%) and stomach (24%), and in moderate frequencies in those from the conjunctiva (19%) and orbit (14%). However, the t(11;18) was only rarely found in MALT lymphomas from the salivary gland (1%) and was absent in those from the thyroid, skin, liver, and other rare site. 14 The prevalence of the t(14;18) in the present study was 10% in the group of MALT lymphomas and 23% in the group of MALT lymphomas involving the parotid gland or the conjunctiva. Interestingly, we found a strong correlation between the occurrence of the two main MLT/MALT1-associated translocations, t(11;18) and t(14;18), and the site of origin of the underlying MALT lymphoma. The t(14;18) was most frequently found in MALT lymphomas of the parotid gland, which rarely harbor the t(11;18), and was absent in pulmonary and gastrointestinal MALT lymphomas, which showed the highest frequencies of the t(11;18). A similar correlation has been found in a recent study, where the t(14;18)(q32;q21) has been detected in MALT lymphomas arising from the liver, ocular adnexa, parotid gland, and skin but not in any of the MALT lymphomas arising from the gastrointestinal tract, lung, thyroid, and breast. 18 Together, these data would indicate that the genetic abnormalities in MALT lymphomas reflect their site of origin and possibly either environmental or autoimmune causes. Gastric MALT lymphomas usually develop in a background of chronic Helicobacter pylori gastritis, whereas MALT lymphomas of the parotid glands are frequently found in patients with Sjö grens' syndrome and autoimmune MESA, as in the present study.
Since the MLT/MALT1 gene lies about 5 Mb centromeric to the BCL2 gene, its involvement in the 18q21 amplicon observed in several subtypes of NHL has been suggested. 17 However, in our study, amplifications of MLT/MALT1 were not observed in any of the cases. In the recently published investigation by Sánchez-Izquierdo et al, 17 only one of the five MALT lymphomas and none of the 35 splenic MZBCL analyzed by interphase FISH revealed a low-level amplification of MLT/ MALT1 and BCL2 (five copies of each). In the same study, amplification of MLT/MALT1 without coamplification of BCL2 was detected by array CGH in two of the 40 analyzed cell lines derived from various subtypes of B-cell NHL. These two cell lines were derived from a MZBCL and a Burkitt's lymphoma, respectively, and displayed high-levels of MLT/MALT1 RNA and protein expression. 17 The authors conclude that MLT/MALT1 and BCL2 are independent targets of amplification in NHL.
In our study, trisomy or polysomy of chromosome 18 was observed in 13 cases, including four extranodal MALT lymphomas, two nodal, and seven splenic MZBCL ( Table 2) . These data are in accordance with previous reports, which showed a similar prevalence of trisomy 18 in MZBCL. [25] [26] [27] The genetic mechanism by which aneuploidy of chromosome 18, especially trisomy 18, may contribute to neoplastic transformation or disease progression of MZBCL is not known. A gene dosage effect resulting from a higher copy number of MLT/ MALT1 could be suggested.
Interestingly, two of our cases revealed a deletion of MLT/ MALT1 and BCL2, a finding that has not been described so far ( Table 2 ). The pathogenetic importance of an MLT/MALT1 deletion remains to be determined.
We conclude, that the applied interphase FISH assay is an effective method to detect translocations, amplifications and over-representations of MLT/MALT1. The translocations t(11;18)(q21;q21) and t(14;18)(q21;q32) are the main structural aberrations involving MLT/MALT1 in MALT lymphomas, whereas true amplifications of MLT/MALT1 occur rarely in MZBCL.
